NR565 Advanced Pharmacology | Midterm Exam | Chamberlain 2026/2027
MIDTERM EXAM: NR565 / NR 565 ADVANCED
PHARMACOLOGY
CARE OF THE FUNDAMENTALS EXAM — QUESTIONS &
VERIFIED ANSWERS (2026/2027 UPDATE) —
CHAMBERLAIN
150-Question Comprehensive Examination | Aligned with Chamberlain NR565 Syllabus, AACN Essentials of Master's
Education, and Advanced Practice Pharmacotherapeutics Standards
Section 1: Pharmacokinetics & Pharmacodynamics
Absorption, distribution, metabolism, excretion, receptor theory, dose-response, therapeutic index.
Q1. A 68-year-old patient with cirrhosis is prescribed a drug that undergoes extensive hepatic first-pass
metabolism. Compared to a healthy adult, the oral bioavailability of this drug will most likely be:
A. Decreased due to enhanced metabolism
B. Increased due to impaired first-pass metabolism *[CORRECT]*
C. Unchanged because the liver compensates
D. Decreased due to delayed gastric emptying
Correct Answer: B
Rationale: Cirrhosis impairs hepatic enzyme activity and shunts portal blood away from hepatocytes, reducing first-pass
metabolism and raising oral bioavailability (AUC). Decreased or unchanged bioavailability contradicts the impaired extraction.
Delayed gastric emptying affects rate, not extent of absorption.
Q2. A drug with a half-life of 12 hours is administered once daily. Approximately how long does it take to
reach steady state?
A. 12 hours
B. 24 hours
C. 60 hours *[CORRECT]*
D. 240 hours
Correct Answer: C
Rationale: Steady state is reached in approximately 4–5 half-lives. With t½ = 12 h, 5 × 12 = 60 h (~2.5 days). The other
options are too short (1–2 half-lives) or far too long.
Q3. Which route of administration is most likely to bypass first-pass hepatic metabolism?
A. Oral
B. Sublingual *[CORRECT]*
C. Enteric-coated oral
D. Rectal (lower rectum only partially)
Correct Answer: B
Rationale: Sublingual absorption enters the systemic circulation directly via the superior vena cava, bypassing the portal
circulation and first-pass metabolism. Oral and enteric-coated routes go through the portal system. Rectal is only partially
bypassed.
Q4. A weak acid drug (pKa 4.0) is in the stomach (pH 1.5). Most of the drug will be in which form, and how
does this affect absorption?
A. Ionized; poorly absorbed
B. Un-ionized; well absorbed *[CORRECT]*
C. Ionized; well absorbed
D. Un-ionized; poorly absorbed
Page 1
,NR565 Advanced Pharmacology | Midterm Exam | Chamberlain 2026/2027
Correct Answer: B
Rationale: Weak acids are un-ionized in acidic environments (pH < pKa), favoring membrane crossing. In the stomach (pH
1.5), a weak acid with pKa 4 is mostly un-ionized and well absorbed. Ionized forms cross membranes poorly.
Q5. Which factor is most likely to increase the volume of distribution (Vd) of a lipophilic drug in a neonate?
A. Increased plasma protein binding
B. Higher total body water and fat content *[CORRECT]*
C. Mature blood-brain barrier
D. Increased hepatic enzyme activity
Correct Answer: B
Rationale: Neonates have a higher percentage of total body water and reduced plasma protein binding, increasing Vd for
water-soluble and many lipophilic drugs. Mature BBB (false in neonates) and increased enzyme activity (also immature) would
not raise Vd.
Q6. A drug that is a substrate of CYP3A4 is co-administered with clarithromycin (a strong CYP3A4
inhibitor). The expected effect on substrate drug levels is:
A. Decreased; need to increase dose
B. Increased; risk of toxicity *[CORRECT]*
C. Unchanged
D. Decreased; risk of therapeutic failure
Correct Answer: B
Rationale: Inhibition of CYP3A4 reduces metabolism of the substrate, increasing plasma concentrations and the risk of toxicity.
The dose should typically be reduced or the combination avoided. Decreased or unchanged levels contradict the inhibitory
mechanism.
Q7. Which statement best describes the difference between potency and efficacy?
A. Potency is the maximum effect a drug can produce; efficacy is the dose needed
B. Potency refers to the dose required to produce an effect (EC50); efficacy is the maximum effect achievable
(Emax) *[CORRECT]*
C. Potency and efficacy are interchangeable
D. Efficacy refers to drug safety; potency refers to drug selectivity
Correct Answer: B
Rationale: Potency reflects the concentration/dose producing 50% of the maximal effect (EC50); a lower EC50 means higher
potency. Efficacy (Emax) is the maximum therapeutic effect. They are not interchangeable, and neither directly equals safety or
selectivity.
Q8. A partial agonist at a receptor compared with a full agonist will:
A. Always produce a greater maximal effect in the presence of a full agonist
B. Produce a lower maximal effect and may antagonize a full agonist at the same receptor *[CORRECT]*
C. Have zero affinity for the receptor
D. Always behave as an inverse agonist
Correct Answer: B
Rationale: A partial agonist has lower intrinsic activity, producing a submaximal response, and in the presence of a full agonist
can act as a competitive antagonist. Partial agonists have affinity; they are not inverse agonists, which reduce constitutive
receptor activity.
Q9. A drug with a narrow therapeutic index (TI) requires which of the following monitoring strategies?
A. No monitoring needed
B. Routine clinical observation only
C. Therapeutic drug monitoring (TDM) with plasma levels *[CORRECT]*
D. Monitoring only after toxicity occurs
Correct Answer: C
Page 2
,NR565 Advanced Pharmacology | Midterm Exam | Chamberlain 2026/2027
Rationale: Narrow TI drugs (e.g., warfarin, digoxin, vancomycin, phenytoin) require TDM because toxic and therapeutic
ranges are close, and individual variation is large. Clinical observation alone is insufficient, and waiting for toxicity is unsafe.
Q10. A patient with a creatinine clearance of 25 mL/min is prescribed a renally cleared drug. The prescriber
should:
A. Use the standard adult dose
B. Reduce the dose or extend the dosing interval *[CORRECT]*
C. Increase the dose to compensate
D. Switch to the intramuscular route
Correct Answer: B
Rationale: Renally cleared drugs accumulate in renal impairment; reducing the dose and/or extending the interval maintains
safe plasma concentrations. Standard or increased dosing risks toxicity; the IM route does not solve clearance issues.
Q11. First-order kinetics means that:
A. A constant amount of drug is eliminated per unit time
B. A constant fraction of drug is eliminated per unit time *[CORRECT]*
C. Drug elimination is independent of concentration
D. All drug is eliminated instantly
Correct Answer: B
Rationale: First-order kinetics eliminates a constant fraction per unit time, proportional to plasma concentration. Zero-order
eliminates a constant amount per unit time (e.g., ethanol, high-dose phenytoin). The other options mischaracterize first-order
kinetics.
Q12. The loading dose of a drug is primarily determined by:
A. Half-life only
B. Volume of distribution and desired plasma concentration *[CORRECT]*
C. Clearance only
D. Bioavailability only
Correct Answer: B
Rationale: Loading dose = Vd × desired Cp / bioavailability. It rapidly achieves the target concentration independent of
clearance. Half-life and clearance determine maintenance dosing and time to steady state, not loading dose.
Q13. A drug with high protein binding (>95%) administered to a patient with low serum albumin will have:
A. Higher free (active) drug levels and increased effect/toxicity risk *[CORRECT]*
B. Lower free drug levels and reduced effect
C. Unchanged free fraction
D. Increased total drug clearance
Correct Answer: A
Rationale: Reduced albumin decreases binding sites, raising the free fraction of highly bound drugs and increasing
effect/toxicity risk. Total drug levels may fall as more free drug is available for clearance, but free levels (the active moiety)
rise.
Q14. Cytochrome P450 enzyme induction by rifampin will result in:
A. Increased metabolism of co-administered substrates and possible therapeutic failure *[CORRECT]*
B. Decreased metabolism of substrates and toxicity
C. No change in substrate metabolism
D. Immediate inhibition of all CYP enzymes
Correct Answer: A
Rationale: Rifampin induces CYP3A4, 2C9, and others, increasing substrate metabolism and reducing efficacy of drugs such as
oral contraceptives and warfarin. Induction does not cause toxicity or immediate inhibition.
Page 3
, NR565 Advanced Pharmacology | Midterm Exam | Chamberlain 2026/2027
Q15. A beta-1 selective antagonist produces its therapeutic effect in heart failure through which
pharmacodynamic mechanism?
A. Alpha-1 receptor blockade
B. Decreased sympathetic stimulation of the heart via beta-1 blockade *[CORRECT]*
C. Muscarinic receptor agonism
D. ACE inhibition
Correct Answer: B
Rationale: Beta-1 selective blockers (e.g., metoprolol, carvedilol) reduce heart rate, myocardial oxygen demand, and harmful
remodeling in heart failure via beta-1 blockade. Alpha, muscarinic, and ACE mechanisms describe different drug classes.
Q16. Drug A has an ED50 of 5 mg and Drug B has an ED50 of 50 mg for the same effect. Which statement
is correct?
A. Drug A is more potent than Drug B *[CORRECT]*
B. Drug B is more potent than Drug A
C. Drug A has higher efficacy than Drug B
D. Drug A is safer than Drug B
Correct Answer: A
Rationale: Lower ED50 indicates higher potency. Drug A (ED50 5 mg) is more potent than Drug B. Potency does not equal
efficacy (Emax) or safety, which require separate data (e.g., TD50, LD50).
Q17. Bioavailability of an intravenous drug is by definition:
A. 0%
B. 100% *[CORRECT]*
C. 50%
D. Variable depending on patient weight
Correct Answer: B
Rationale: IV administration delivers the entire dose into systemic circulation, so bioavailability is 100% by definition. Oral
bioavailability varies due to absorption and first-pass metabolism; IV is the reference standard.
Q18. A patient taking warfarin (highly protein-bound) starts furosemide, which is also highly
protein-bound. The most likely clinical consequence is:
A. No interaction expected
B. Displacement of warfarin from albumin, transiently increasing free warfarin and INR *[CORRECT]*
C. Decreased warfarin effect due to enhanced metabolism
D. Reduced renal clearance of furosemide
Correct Answer: B
Rationale: Displacement interactions raise free warfarin transiently, increasing INR/bleeding risk, especially with rapid loading.
Sustained effects depend on clearance compensation. The mechanism is not enhanced metabolism or furosemide clearance
change.
Section 2: Pharmacogenomics & Individualized Therapy
CYP2C9/CYP2C19/CYP2D6, VKORC1, HLA-B*5701, TPMT and clinical applications.
Q19. A patient beginning clopidogrel is found to be a CYP2C19 poor metabolizer. The most appropriate
action is:
A. Increase the clopidogrel dose
B. Avoid clopidogrel; consider alternative antiplatelet (e.g., prasugrel/ticagrelor) *[CORRECT]*
C. Add a CYP2C19 inducer
D. Continue standard dosing without change
Correct Answer: B
Page 4
MIDTERM EXAM: NR565 / NR 565 ADVANCED
PHARMACOLOGY
CARE OF THE FUNDAMENTALS EXAM — QUESTIONS &
VERIFIED ANSWERS (2026/2027 UPDATE) —
CHAMBERLAIN
150-Question Comprehensive Examination | Aligned with Chamberlain NR565 Syllabus, AACN Essentials of Master's
Education, and Advanced Practice Pharmacotherapeutics Standards
Section 1: Pharmacokinetics & Pharmacodynamics
Absorption, distribution, metabolism, excretion, receptor theory, dose-response, therapeutic index.
Q1. A 68-year-old patient with cirrhosis is prescribed a drug that undergoes extensive hepatic first-pass
metabolism. Compared to a healthy adult, the oral bioavailability of this drug will most likely be:
A. Decreased due to enhanced metabolism
B. Increased due to impaired first-pass metabolism *[CORRECT]*
C. Unchanged because the liver compensates
D. Decreased due to delayed gastric emptying
Correct Answer: B
Rationale: Cirrhosis impairs hepatic enzyme activity and shunts portal blood away from hepatocytes, reducing first-pass
metabolism and raising oral bioavailability (AUC). Decreased or unchanged bioavailability contradicts the impaired extraction.
Delayed gastric emptying affects rate, not extent of absorption.
Q2. A drug with a half-life of 12 hours is administered once daily. Approximately how long does it take to
reach steady state?
A. 12 hours
B. 24 hours
C. 60 hours *[CORRECT]*
D. 240 hours
Correct Answer: C
Rationale: Steady state is reached in approximately 4–5 half-lives. With t½ = 12 h, 5 × 12 = 60 h (~2.5 days). The other
options are too short (1–2 half-lives) or far too long.
Q3. Which route of administration is most likely to bypass first-pass hepatic metabolism?
A. Oral
B. Sublingual *[CORRECT]*
C. Enteric-coated oral
D. Rectal (lower rectum only partially)
Correct Answer: B
Rationale: Sublingual absorption enters the systemic circulation directly via the superior vena cava, bypassing the portal
circulation and first-pass metabolism. Oral and enteric-coated routes go through the portal system. Rectal is only partially
bypassed.
Q4. A weak acid drug (pKa 4.0) is in the stomach (pH 1.5). Most of the drug will be in which form, and how
does this affect absorption?
A. Ionized; poorly absorbed
B. Un-ionized; well absorbed *[CORRECT]*
C. Ionized; well absorbed
D. Un-ionized; poorly absorbed
Page 1
,NR565 Advanced Pharmacology | Midterm Exam | Chamberlain 2026/2027
Correct Answer: B
Rationale: Weak acids are un-ionized in acidic environments (pH < pKa), favoring membrane crossing. In the stomach (pH
1.5), a weak acid with pKa 4 is mostly un-ionized and well absorbed. Ionized forms cross membranes poorly.
Q5. Which factor is most likely to increase the volume of distribution (Vd) of a lipophilic drug in a neonate?
A. Increased plasma protein binding
B. Higher total body water and fat content *[CORRECT]*
C. Mature blood-brain barrier
D. Increased hepatic enzyme activity
Correct Answer: B
Rationale: Neonates have a higher percentage of total body water and reduced plasma protein binding, increasing Vd for
water-soluble and many lipophilic drugs. Mature BBB (false in neonates) and increased enzyme activity (also immature) would
not raise Vd.
Q6. A drug that is a substrate of CYP3A4 is co-administered with clarithromycin (a strong CYP3A4
inhibitor). The expected effect on substrate drug levels is:
A. Decreased; need to increase dose
B. Increased; risk of toxicity *[CORRECT]*
C. Unchanged
D. Decreased; risk of therapeutic failure
Correct Answer: B
Rationale: Inhibition of CYP3A4 reduces metabolism of the substrate, increasing plasma concentrations and the risk of toxicity.
The dose should typically be reduced or the combination avoided. Decreased or unchanged levels contradict the inhibitory
mechanism.
Q7. Which statement best describes the difference between potency and efficacy?
A. Potency is the maximum effect a drug can produce; efficacy is the dose needed
B. Potency refers to the dose required to produce an effect (EC50); efficacy is the maximum effect achievable
(Emax) *[CORRECT]*
C. Potency and efficacy are interchangeable
D. Efficacy refers to drug safety; potency refers to drug selectivity
Correct Answer: B
Rationale: Potency reflects the concentration/dose producing 50% of the maximal effect (EC50); a lower EC50 means higher
potency. Efficacy (Emax) is the maximum therapeutic effect. They are not interchangeable, and neither directly equals safety or
selectivity.
Q8. A partial agonist at a receptor compared with a full agonist will:
A. Always produce a greater maximal effect in the presence of a full agonist
B. Produce a lower maximal effect and may antagonize a full agonist at the same receptor *[CORRECT]*
C. Have zero affinity for the receptor
D. Always behave as an inverse agonist
Correct Answer: B
Rationale: A partial agonist has lower intrinsic activity, producing a submaximal response, and in the presence of a full agonist
can act as a competitive antagonist. Partial agonists have affinity; they are not inverse agonists, which reduce constitutive
receptor activity.
Q9. A drug with a narrow therapeutic index (TI) requires which of the following monitoring strategies?
A. No monitoring needed
B. Routine clinical observation only
C. Therapeutic drug monitoring (TDM) with plasma levels *[CORRECT]*
D. Monitoring only after toxicity occurs
Correct Answer: C
Page 2
,NR565 Advanced Pharmacology | Midterm Exam | Chamberlain 2026/2027
Rationale: Narrow TI drugs (e.g., warfarin, digoxin, vancomycin, phenytoin) require TDM because toxic and therapeutic
ranges are close, and individual variation is large. Clinical observation alone is insufficient, and waiting for toxicity is unsafe.
Q10. A patient with a creatinine clearance of 25 mL/min is prescribed a renally cleared drug. The prescriber
should:
A. Use the standard adult dose
B. Reduce the dose or extend the dosing interval *[CORRECT]*
C. Increase the dose to compensate
D. Switch to the intramuscular route
Correct Answer: B
Rationale: Renally cleared drugs accumulate in renal impairment; reducing the dose and/or extending the interval maintains
safe plasma concentrations. Standard or increased dosing risks toxicity; the IM route does not solve clearance issues.
Q11. First-order kinetics means that:
A. A constant amount of drug is eliminated per unit time
B. A constant fraction of drug is eliminated per unit time *[CORRECT]*
C. Drug elimination is independent of concentration
D. All drug is eliminated instantly
Correct Answer: B
Rationale: First-order kinetics eliminates a constant fraction per unit time, proportional to plasma concentration. Zero-order
eliminates a constant amount per unit time (e.g., ethanol, high-dose phenytoin). The other options mischaracterize first-order
kinetics.
Q12. The loading dose of a drug is primarily determined by:
A. Half-life only
B. Volume of distribution and desired plasma concentration *[CORRECT]*
C. Clearance only
D. Bioavailability only
Correct Answer: B
Rationale: Loading dose = Vd × desired Cp / bioavailability. It rapidly achieves the target concentration independent of
clearance. Half-life and clearance determine maintenance dosing and time to steady state, not loading dose.
Q13. A drug with high protein binding (>95%) administered to a patient with low serum albumin will have:
A. Higher free (active) drug levels and increased effect/toxicity risk *[CORRECT]*
B. Lower free drug levels and reduced effect
C. Unchanged free fraction
D. Increased total drug clearance
Correct Answer: A
Rationale: Reduced albumin decreases binding sites, raising the free fraction of highly bound drugs and increasing
effect/toxicity risk. Total drug levels may fall as more free drug is available for clearance, but free levels (the active moiety)
rise.
Q14. Cytochrome P450 enzyme induction by rifampin will result in:
A. Increased metabolism of co-administered substrates and possible therapeutic failure *[CORRECT]*
B. Decreased metabolism of substrates and toxicity
C. No change in substrate metabolism
D. Immediate inhibition of all CYP enzymes
Correct Answer: A
Rationale: Rifampin induces CYP3A4, 2C9, and others, increasing substrate metabolism and reducing efficacy of drugs such as
oral contraceptives and warfarin. Induction does not cause toxicity or immediate inhibition.
Page 3
, NR565 Advanced Pharmacology | Midterm Exam | Chamberlain 2026/2027
Q15. A beta-1 selective antagonist produces its therapeutic effect in heart failure through which
pharmacodynamic mechanism?
A. Alpha-1 receptor blockade
B. Decreased sympathetic stimulation of the heart via beta-1 blockade *[CORRECT]*
C. Muscarinic receptor agonism
D. ACE inhibition
Correct Answer: B
Rationale: Beta-1 selective blockers (e.g., metoprolol, carvedilol) reduce heart rate, myocardial oxygen demand, and harmful
remodeling in heart failure via beta-1 blockade. Alpha, muscarinic, and ACE mechanisms describe different drug classes.
Q16. Drug A has an ED50 of 5 mg and Drug B has an ED50 of 50 mg for the same effect. Which statement
is correct?
A. Drug A is more potent than Drug B *[CORRECT]*
B. Drug B is more potent than Drug A
C. Drug A has higher efficacy than Drug B
D. Drug A is safer than Drug B
Correct Answer: A
Rationale: Lower ED50 indicates higher potency. Drug A (ED50 5 mg) is more potent than Drug B. Potency does not equal
efficacy (Emax) or safety, which require separate data (e.g., TD50, LD50).
Q17. Bioavailability of an intravenous drug is by definition:
A. 0%
B. 100% *[CORRECT]*
C. 50%
D. Variable depending on patient weight
Correct Answer: B
Rationale: IV administration delivers the entire dose into systemic circulation, so bioavailability is 100% by definition. Oral
bioavailability varies due to absorption and first-pass metabolism; IV is the reference standard.
Q18. A patient taking warfarin (highly protein-bound) starts furosemide, which is also highly
protein-bound. The most likely clinical consequence is:
A. No interaction expected
B. Displacement of warfarin from albumin, transiently increasing free warfarin and INR *[CORRECT]*
C. Decreased warfarin effect due to enhanced metabolism
D. Reduced renal clearance of furosemide
Correct Answer: B
Rationale: Displacement interactions raise free warfarin transiently, increasing INR/bleeding risk, especially with rapid loading.
Sustained effects depend on clearance compensation. The mechanism is not enhanced metabolism or furosemide clearance
change.
Section 2: Pharmacogenomics & Individualized Therapy
CYP2C9/CYP2C19/CYP2D6, VKORC1, HLA-B*5701, TPMT and clinical applications.
Q19. A patient beginning clopidogrel is found to be a CYP2C19 poor metabolizer. The most appropriate
action is:
A. Increase the clopidogrel dose
B. Avoid clopidogrel; consider alternative antiplatelet (e.g., prasugrel/ticagrelor) *[CORRECT]*
C. Add a CYP2C19 inducer
D. Continue standard dosing without change
Correct Answer: B
Page 4
